Praed Pharmaceuticals is biopharmaceutical company founded by industry experts. Our mission is to deliver a next generation treatment for Crohn’s disease. We are developing a promising oral compound, cadazolid, for the treatment of Crohn’s disease.
Products, services, technology
Cadazolid will be developed in Crohn’s disease. MAP (Mycobacterium avium subspecies paratuberculosis) infections are implicated as the cause of Crohn’s disease. Cadazolid is highly active against MAP. Due to an earlier PI-III development program, the clinical profile and CMC are well known.
Investing or Partnering: We are planning, initiating, and conducting a Phase 2a clinical study, for which we are currently looking for funds as investments or partnering.